Personalised medicine has exploited K-RAS-mutation-specific tumour differences for the development of mutation-selective anti-RAS strategies; thus, it could be beneficial to place K-RAS4A in the spotlight and perhaps achieve more selective cancer treatment strategies. Here, KRAS is linked to cancer.